- The role of the gut microbiome and diet in the pathogenesis of non-alcoholic fatty liver disease
-
Jennison E, Byrne CD
- KMID: 2511448
- Clin Mol Hepatol.
- 2021 Jan;27(1):22-43.
- doi: 10.3350/cmh.2020.0129
Non-alcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver disease, with a prevalence that is increasing in parallel with the global rise in obesity and type 2... -
- CITED
-
- Close
- SHARE
-
- Close
- Noninvasive serum biomarkers for liver fibrosis in NAFLD: current and future
-
Reinson T, Buchanan RM, Byrne CD
- KMID: 2539798
- Clin Mol Hepatol.
- 2023 Feb;29(Suppl):S157-S170.
- doi: 10.3350/cmh.2022.0348
In the last 20 years, noninvasive serum biomarkers to identify liver fibrosis in patients with non-alcoholic fatty liver disease (NAFLD) have been developed, validated against liver biopsy (the gold standard... -
- CITED
-
- Close
- SHARE
-
- Close
- Lifestyle Interventions for Non-Obese Patients Both with, and at Risk, of Non-Alcoholic Fatty Liver Disease
-
Zhang XL, Wang TY, Targher G, Byrne CD, Zheng MH
- KMID: 2530178
- Diabetes Metab J.
- 2022 May;46(3):391-401.
- doi: 10.4093/dmj.2022.0048
Non-alcoholic fatty liver disease occurring in non-obese subjects (the so-called non-obese NAFLD) is a highly prevalent but neglected liver condition, which is closely associated with metabolic disorders and suboptimal lifestyles.... -
- CITED
-
- Close
- SHARE
-
- Close
- Old and new classes of glucose-lowering agents as treatments for non-alcoholic fatty liver disease: A narrative review
-
Miao L, Xu J, Targher G, Byrne CD, Zheng MH
- KMID: 2534339
- Clin Mol Hepatol.
- 2022 Oct;28(4):725-738.
- doi: 10.3350/cmh.2022.0015
Non-alcoholic fatty liver disease (NAFLD) has become the most common chronic liver disease with a global prevalence of about 55% in people with type 2 diabetes mellitus (T2DM). T2DM, obesity... -
- CITED
-
- Close
- SHARE
-
- Close
